scholarly journals A novel therapeutic anti‑CD55 monoclonal antibody inhibits the proliferation and metastasis of colorectal cancer cells

2019 ◽  
Author(s):  
So Dho ◽  
Eun Cho ◽  
Ji Lee ◽  
So‑Young Lee ◽  
Sung Jung ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Monoclonal Antibody ◽  
Cancer Cells ◽  
Colorectal Cancer Cells ◽  
Proliferation And Metastasis ◽  
Novel Therapeutic

scholarly journals Gold nanoparticles conjugated with anti-CD133 monoclonal antibody and 5-fluorouracil chemotherapeutic agent as nanocarriers for cancer cell targeting

RSC Advances ◽  
2021 ◽  
Vol 11 (26) ◽  
pp. 16131-16141
Author(s):  
Manali Haniti Mohd-Zahid ◽  
Siti Nadiah Zulkifli ◽  
Che Azurahanim Che Abdullah ◽  
JitKang Lim ◽  
Sharida Fakurazi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Monoclonal Antibody ◽  
Gold Nanoparticles ◽  
Cancer Cells ◽  
Cancer Cell ◽  
Chemotherapeutic Agent ◽  
Cell Targeting ◽  
Specific Targeting ◽  
Colorectal Cancer Cells ◽  
Cancer Cell Targeting

5-FU-PEGylated AuNPs-CD133 is designed to improve specific targeting of 5-FU against colorectal cancer cells which abundantly express CD133.

TRIP6, as a target of miR-7, regulates the proliferation and metastasis of colorectal cancer cells

2019 ◽  
Vol 514 (1) ◽  
pp. 231-238 ◽  
Author(s):  
Yiting Ling ◽  
Chenxi Cao ◽  
Sengjuan Li ◽  
Min Qiu ◽  
Guixing Shen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Cells ◽  
Colorectal Cancer Cells ◽  
Proliferation And Metastasis

scholarly journals SIRT2, a direct target of miR‐212‐5p, suppresses the proliferation and metastasis of colorectal cancer cells

2020 ◽  
Vol 24 (17) ◽  
pp. 9985-9998
Author(s):  
Feng Du ◽  
Zhijun Li ◽  
Guohua Zhang ◽  
Si Shaoyan ◽  
Dejun Geng ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Cells ◽  
Colorectal Cancer Cells ◽  
Proliferation And Metastasis ◽  
Direct Target

scholarly journals Panitumumab and cetuximab affect differently miRNA expression in colorectal cancer cells

2021 ◽  
Author(s):  
Romain Chautard ◽  
Laetitia Corset ◽  
Sajida Ibrahim ◽  
Céline Desvignes ◽  
Gilles Paintaud ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Monoclonal Antibody ◽  
Monoclonal Antibodies ◽  
Cancer Cells ◽  
Two Phase ◽  
Colorectal Cancer Cells ◽  
Significant Expression ◽  
Antibody Resistance ◽  
Phase Process

Structured abstract Background & aim: Resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer (CRC) is frequent and prognostic biomarkers are lacking. MicroRNAs (miR) are good candidates in this context. We aimed to characterize cetuximab and panitumumab exposure influence on miR expression in colorectal cancer cells to identify those regulating the EGFR pathway and implicated in resistance to treatment. Finally, we aimed to identify miR expression in serum of patients with advanced CRC treated with cetuximab or panitumumab. Results: Cetuximab and panitumumab exposure induced significant expression variations of 17 miR out of a miRnome panel of 752. Six of those miR interacted with at least one downstream element of the EGFR pathway. Conclusion: After the bioinformatics two-phase process, 5 miR rarely described before could be potential actors of anti-EGFR monoclonal antibody resistance: miR-95-3p, miR-139-5p, miR-145-5p, miR-429 and miR-1247-5p. In vivo, we detected the expression of miR-139-5p and miR-145-5p in serum of patients with metastatic CRC.

Sign in / Sign up

Export Citation Format

Share Document